Deutsche Bank initiated coverage of Biohaven (BHVN) with a Buy rating and $65 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven Ltd.’s Promising Outlook for Troriluzole in Spinocerebellar Ataxia Amidst FDA Decision
- Pfizer to pay ~$60M to settle Medicare false claims
- Biohaven Showcases TRAP Degraders at J.P. Morgan Conference
- Biohaven announces 2025 anticipated milestones
- Biohaven enters multi-target collaboration with Merus